Evenity™ (romosozumab-aqqg)

Evenity is covered only for postmenopausal women with osteoporosis at high fracture risk who meet specified BMD (T‑score ≤‑2.5 or low bone mass with high risk) or fracture criteria and who have tried/failed or are intolerant to bisphosphonates (or cannot take oral bisphosphonates); it is not covered for non‑FDA indications or non‑postmenopausal populations. Key requirements: documentation of fracture history or specific T‑scores, evidence of prior bisphosphonate therapy/failure/intolerance or documented inability to take oral bisphosphonates (CrCl <35 mL/min if citing renal impairment), and authorization is limited to 12 monthly 210 mg subcutaneous doses.

"Treatment duration limited to 12 monthly doses (Approval duration: 12 months (lifetime))."

Sign up to see full coverage criteria, indications, and limitations.